rh-BNP 联合阿托伐他汀治疗急性心梗后心衰的临床疗效及对患者血清 cTn-I、Myo、CK-MB 水平的影响.

Objective: To study Clinical efficacy of Intravenous rh-bnp Combined with Atorvastatin in the Treatment of Heart Failure after Acute Myocardial Infarction and Its Effect on the Serum Levels of Myocardial troponin (cardiac troponin, cTn-I), Myoglobin (Myoglobin, Myo), creatine kinase isoenzyme (CK-MB). Methods: 72 patients with heart failure after acute myocardial infarction admitted to our hospital from February 2017 to January 2019 were selected, were divided into observation group 38 cases and control group 34 cases according to random number table method. The control group was treated with atorvastatin, and rh-bnp was added to the observation group on the basis of the control group to observe and compare the clinical efficacy of the two groups, the changes of serum ctn-i, Myo and ck-mb levels before and after treatment, and the occurrence of adverse reactions after treatment. Results: After treatment, the total effective rate of the observation group was significantly higher than that of the control group (P<0.05), and the serum levels of ctn-i, Myo and ck-mb were significantly lower than those of the control group [(0.23± 0.10) vs (0.16± 0.08), (27.54 ± 3.86) vs (21.62 ± 2.54), (70.82± 9.25) vs (61.28± 8.33)](P<0.05). The overall incidence of adverse reactions after treatment in the observation group was 7.89%, significantly lower than that in the control group (26.47%, P<0.05). Conclusion: Compared with atorvastatin alone, intravenous rh-bnp combined with atorvastatin in the treatment of heart failure after acute myocardial infarction can significantly improve the clinical efficacy and safety, and effectively reduce serum levels of ctn-i, Myo and ck-mb. [ABSTRACT FROM AUTHOR]